Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Oliver & Co who wrote (2739)	11/12/1997 8:43:00 PM
From: Izzy	Read Replies (1) \| Respond to of 6136

Dr. Oliver: Again, thanks for info. Wouldn't it seem reasonable that AGPH would be continuing to develop another HIV protease inhibitor or to make modifications of Viracept (considering that other companies are already working on other PIs)? Why not combine Viracept and Saquinavir in a pill/capsule (BCHE already offers combined AZT/3TC)? That should make drug compliance much better. BTW, it bugs me that traders are shorting AGPH at 41. I guess they obviously think that they are going to make money? Perhaps they read Bill's previous post today. I appreciate the advice of staying away from margin investing but I couldn't resist at the current price.